CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
June 27th 2025
Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and multiple myeloma, respectively.
Distress Score Could Shape Myeloma Treatment Interventions
March 6th 2018While recent breakthroughs have led to more treatment options for multiple myeloma, patients are also experiencing new side effects, stressful financial issues and psychological burdens. In turn, recent research found that this increased distress may actually have negative implications for patient outcomes.
Stem Cell Transplantation Remains Standard of Care in Multiple Myeloma
February 19th 2018Patients with multiple myeloma who are eligible for stem cell transplantation should still be considered for high-dose therapy (HDT) even in the novel agent era, according to the authors of a study recently published in the Journal of the American Medical Association Oncology.
Myeloma Precursor May Cause Disease Progression, Even 30 Years Later
February 19th 2018An abnormal protein found in the blood – called monoclonal gammopathy of undetermined significance (MGUS) – may lead to multiple myeloma progression, even after 30 years of disease stability, according to study results published in the New England Journal of Medicine.
Exploring Unanswered Questions on CAR-T Cell Therapy in Myeloma
January 29th 2018The success of CAR- (chimeric antigen receptor) T cell therapy is causing landmark change in the way that patients with multiple myeloma are being treated, but more research needs to be done to better understand the role that these agents will play.
Darzalex Combination Granted Priority Review for Myeloma Treatment
January 22nd 2018The Food and Drug Administration (FDA) granted priority review to the combination use of Darzalex (daratumumab), Velcade (bortezomib), melphalan and prednisone for the treatment of newly diagnosed patients with multiple myeloma who are not eligible for autologous stem cell transplant (ACST).
Kyprolis Label Update Approved for Myeloma Treatment
January 18th 2018The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.
Despite Clinical Efficacy, Only Certain Myeloma Treatments Are Cost-Effective
January 17th 2018Over the past few years, the Food and Drug Administration (FDA) has approved a variety of triplet combinations for the treatment of patients with multiple myeloma. However, little is known which regimens have the best economic impact, without sacrificing clinical outcomes that is.
Popular Myeloma Drug Associated With Higher Rates of Heart Toxicity
January 5th 2018A drug commonly used to treat patients with multiple myeloma may lead to an increased risk of cardiovascular events such as heart attacks, according to recent research conducted at the Abramson Cancer Center of the University of Pennsylvania.
What Comes Next for Cancer Survivors?
December 4th 2017At the National Comprehensive Cancer Network® (NCCN)’s Patient Advocacy Summit – a meeting designed to share best practices for survivorship planning care among advocacy organizations – Yelak Biru shared his story of survivorship, and how he has been able to integrate multiple myeloma into his life for more than two decades.
Drug Granted Breakthrough Status to Treat Relapsed or Refractory Myeloma
November 3rd 2017A new drug, GSK2857916, was granted a breakthrough therapy designation by the FDA to treat patients who have relapsed or refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the agent.
Individualized Treatment Needed for Relapsed, Refractory Multiple Myeloma
October 10th 2017Patients with relapsed/refractory multiple myeloma should be given individualized treatment approaches guided by the biology of their disease, frailty of the patient and other comorbidities, said Natalie S. Callander, M.D., who presented on the topic at the NCCN 12th Annual Congress: Hematologic Malignancies in San Francisco, California.
Acupuncture Reduces Symptom Burden in Patients With Multiple Myeloma
September 27th 2017Acupuncture is a powerful resource that has been around for thousands of years. The traditional Chinese medicine is effective in treating chronic pain and headaches, and is now being used by many patients with cancer as a complementary therapy alongside medicinal treatment.